Drug
L-NAME
L-NAME is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
100%(2 trials)
Phase Distribution
Ph phase_2
2
50%
Ph early_phase_1
1
25%
Ph not_applicable
1
25%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(2)
Detailed Status
Completed2
Recruiting2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (25.0%)
Phase 22 (50.0%)
N/A1 (25.0%)
Trials by Status
completed250%
recruiting250%
Recent Activity
2 active trials
Showing 4 of 4
recruitingearly_phase_1
Heat, Microvascular Function and Aging
NCT06633198
recruitingphase_2
Effects of an Antioxidant Supplement on Blood Vessel Health
NCT06424756
completednot_applicable
Role of Nitric Oxide in the Impact of Aging on Myocardial Remodeling
NCT00603720
completedphase_2
Safety and Efficacy of L-NAME and Midodrine to Increase MAP
NCT00835224
Clinical Trials (4)
Showing 4 of 4 trials
NCT06633198Early Phase 1
Heat, Microvascular Function and Aging
NCT06424756Phase 2
Effects of an Antioxidant Supplement on Blood Vessel Health
NCT00603720Not Applicable
Role of Nitric Oxide in the Impact of Aging on Myocardial Remodeling
NCT00835224Phase 2
Safety and Efficacy of L-NAME and Midodrine to Increase MAP
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4